Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Invest New Drugs. 2013 Jun;31(3):493-505. doi: 10.1007/s10637-012-9871-1. Epub 2012 Sep 14.

A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production.

Author information

  • 1Laboratório de Bioquímica e Biofísica- Instituto Butantan, Av. Vital Brazil, 1500-CEP, 05503-900, São Paulo, SP, Brazil.

Abstract

In cancer-treatment, potentially therapeutic drugs trigger their effects through apoptotic mechanisms. Generally, cell response is manifested by Bcl-2 family protein regulation, the impairment of mitochondrial functions, and ROS production. Notwithstanding, several drugs operate through proteasome inhibition, which, by inducing the accumulation and aggregation of misfolded or unfolded proteins, can lead to endoplasmic reticulum (ER) stress. Accordingly, it was shown that Amblyomin-X, a Kunitz-type inhibitor identified in the transcriptome of the Amblyomma cajennense tick by ESTs sequence analysis of a cDNA library, obtained in recombinant protein form, induces apoptosis in murine renal adenocarcinoma (RENCA) cells by: inducing imbalance between pro- and anti-apoptotic Bcl-2 family proteins, dysfunction/mitochondrial damage, production of reactive oxygen species (ROS), caspase cascade activation, and proteasome inhibition, all ER-stress inductive. Moreover, there was no manifest action on normal mouse-fibroblast cells (NHI3T3), suggesting an Amblyomin-X tumor-cell selectivity. Taken together, these evidences indicate that Amblyomin-X could be a promising candidate for cancer therapy.

PMID:
22975862
[PubMed - indexed for MEDLINE]
PMCID:
PMC3644403
Free PMC Article

Images from this publication.See all images (8)Free text

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk